Cargando…

MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells

Detalles Bibliográficos
Autores principales:	Vella, Laura J, Pasam, Anupama, Dimopoulos, Nektaria, Andrews, Miles, Puaux, Anne-Laure, Louahed, Jamila, Knights, Ashley, Chan, Weisan, Woods, Katherine, Cebon, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991062/ http://dx.doi.org/10.1186/2051-1426-1-S1-P93

Ejemplares similares

Effects of Epithelial to Mesenchymal Transition on T Cell Targeting of Melanoma Cells
por: Woods, Katherine, et al.
Publicado: (2014)

Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials
por: Liu, Mengdong, et al.
Publicado: (2017)

Indeterminate Dendritic Cell Tumor With Persistent Complete Metabolic Response to BRAF/MEK Inhibition
por: Thurner, Lorenz, et al.
Publicado: (2020)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
por: Tutuka, Candani S. A., et al.
Publicado: (2017)

Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ()
por: Vella, Laura J., et al.
Publicado: (2017)

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
por: Campos, Maira P., et al.
Publicado: (2018)

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2
por: Chen, Wenjing, et al.
Publicado: (2023)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
por: Hoyer, Stefanie, et al.
Publicado: (2021)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
por: Da Gama Duarte, Jessica, et al.
Publicado: (2018)

Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition
por: Morales, Delphine, et al.
Publicado: (2021)

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
por: Peiffer, Lukas, et al.
Publicado: (2020)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
por: Tholander, Bengt, et al.
Publicado: (2020)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
por: Pisanu, Maria Elena, et al.
Publicado: (2018)

Successful BRAF/MEK inhibition in a patient with BRAF(V600E)-mutated extrapancreatic acinar cell carcinoma
por: Busch, Elena, et al.
Publicado: (2020)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
por: Liu, Fen, et al.
Publicado: (2017)

Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma
por: Laino, Antonia, et al.
Publicado: (2018)

A Novel HLA-B18 Restricted CD8+ T Cell Epitope Is Efficiently Cross-Presented by Dendritic Cells from Soluble Tumor Antigen
por: Zhao, Rona Y., et al.
Publicado: (2012)

Remarkable response of BRAF(V600E)-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report
por: Li, Hong-Shuai, et al.
Publicado: (2021)

Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial
por: Tian, Jun, et al.
Publicado: (2023)

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
por: Temraz, Sally, et al.
Publicado: (2015)

Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition
por: Allen, Amy, et al.
Publicado: (2019)

Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta‐analysis and systematic review
por: Yu, Qingliang, et al.
Publicado: (2019)

Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
por: Luke, Jason J.
Publicado: (2019)

Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase
por: GLUTSCH, Valerie, et al.
Publicado: (2020)

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
por: Munjapara, Vasu, et al.
Publicado: (2022)

Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity
por: Gadiot, Jules, et al.
Publicado: (2013)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis
por: Chen, Peng, et al.
Publicado: (2017)

Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma
por: Song, Chengli, et al.
Publicado: (2017)

Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells
por: Lamichhane, Astha, et al.
Publicado: (2023)

Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma
por: DiPeri, Timothy P., et al.
Publicado: (2022)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
por: Zhang, Simeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a4khk81p72bbii7d8nol7gcgok